A brief review on the pathogenesis of human diabetic neuropathy: Observations and postulations

International Journal of Diabetes and Metabolism

Volumn 13, Issue 3, 2005, Pages 135-140

  Rajbhandari, S M ^a,b   Piya, M K ^a  

^a LANCASHIRE TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b Chorley and South Ribble Hospital ^*  (United Kingdom)

Author keywords

Diabetes mellitus; Human; Neuropathy; Pain

Indexed keywords

CELL ADHESION MOLECULE; CHOLESTEROL; DIACYLGLYCEROL; LIPOPROTEIN A; NERVE GROWTH FACTOR; POLYOL; PROTEIN KINASE C; TRIACYLGLYCEROL;

AUTOIMMUNITY; CARDIOVASCULAR RISK; CELL STRUCTURE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; DIABETIC NEUROPATHY; ENDOTHELIAL DYSFUNCTION; ESSENTIAL FATTY ACID DEFICIENCY; GLYCATION; GLYCEMIC CONTROL; HEART HEMODYNAMICS; HUMAN; HYPERTENSION; MICROVASCULARIZATION; OBSERVATIONAL STUDY; OXIDATIVE STRESS; SHORT SURVEY; THROMBOCYTE DYSFUNCTION;

EID: 33751226252     PISSN: 16067754     EISSN: None     Source Type: Journal    
DOI: 10.1159/000497581     Document Type: Short Survey

References (60)

1. Boyko EJ. The Epidemiology of diabetic neuropathy. In: Veves A. (ed.), Clinical Management of Diabetic Neuropathy, 1998; pp.1-12. Human Press Totowa: New Jersey.
2. Dyck PJ, Kratz KM, Karnes JL et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43: 817-824.
3. Tesfaye S, Stevens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complication Study. Diabetologia 1996; 39: 1377-1384.
4. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947 and 1973. Diabetes Metab 1977; 1: 245-256.
5. Adler AI, Byoko EJ, Ahroni JH, et al. Risk factors for diabetic peripheral sensory neuropathy: Results of the Seattle Prospective Diabetic Foot study. Diabetes Care 1997; 20: 1162-1167.
6. Maser RE, Usher DC, DeCherney GS. Little association of lipid parameters and large sensory nerve fiber function in diabetes mellitus". J Diabetes Complicat 1996; 10: 54-59.
7. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM Diabetic somatic neuropathies. Diabetes Care 2004; 27: 1458-1486.
8. DCCT. The diabetes control and complications research group. The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
9. UK Prospective diabetes study (UKPDS) group. Intensive blood-glucose control woth sulphonylureas or insulin compared woth conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
10. Ziegler D, Cicmir I, Mayer P, Wiefels K, Gries FA. Somatic and autonomic nerve function during the first year after diagnosis of type 1 (insulin-dependent) diabetes". Diabetes Res 1988; 7: 123-127.
11. Forrest KY, Maser RE, Pambianco G, Becker DJ, Orchard TJ. Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes 1997; 46: 665-670.
12. Solders G, Thalme B, Aguirre-Aquino M, et al. Nerve conduction and autonomic nerve function in diabetic children, A 10-year follow-up study. Acta Paediatrica 1997; 86: 361-366.
13. Allen C, Shen G, Palta M, et al. Long-term hyperglycemia is related to peripheral nerve changes at a diabetes duration of 4 years. The Wisconsin Diabetes Registry. Diabetes Care 1997; 20: 1154-1158.
14. Forsblom CM, Sane T, Groop PH, et al. Risk factors for mortality in type II (non-insulin-dependent) diabetes: evidence of a role for neuropathy and protective effect of HLA-DR4. Diabetologia, 1998; 41: 1253-1262.
15. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352: 341-350
16. Rajbhandari SM, Dent MT, Plater ME, et al. Raised lipid levels in diabetic neuropathy: the Sheffield prospective diabetes study. Diabetes 1999; Suppl, No 1690 Abstract.
17. Lithner F, Bergenheim T, Borssen B, Dahlen G, Nilsson TK. The association of fibrinolysis and hyperlipidaemia with quantitative sensory tests in an epidemiological study of Swedish type 1 diabetic patients. Diabetic Med 1995; 12: 590-594.
18. Mitchell BD, Hawthorne VM, Vinik AI. Cigarette smoking and neuropathy in diabetic patients. Diabetes Care 1990; 13: 434-437.
19. Rajbhandari SM, Dent MT, Plater ME, et al. Increased incidence of diabetic neuropathy on smokers: The Sheffield Prispective Diabetes Study. Diabetologia 2001; 44: Suppl 1; 1143.
20. Fagerberg SE. Diabetic neuropathy: a clinical and histological study on the significance of vascular affection. Acta Med Scand 1959; 164 (Suppl 345): 5-81.
21. Theriault M, Dort J, Sutherland G, Zochodne DW. "Local human sural nerve blood flow in diabetic and other polyneuropathies. Brain 1997; 120: 1131-1138.
22. Tesfaye S, Harris ND, Jakubowski J, et al. Impaired blood flow and arterio-venous shunting in human diabetic neuropathy: a novel technique of nerve photography and fluorescein angiography. Diabetologia 1993; 36: 1266-1274.
23. Malik RA, Veves A, Masson EA, et al. Endoneurial capillary abnormalities in mild human diabetic neuropathy. J Neurol Neurosur PS 1992; 55: 557-561.
24. Newrick PG, Wilson AJ, Jakobowski J, et al. Sural nerve oxygen tension in diabetes. BMJ 1986; 293, 1053-1054.
25. Ibrahim SB, Harris ND, Fahid S, et al. A new minimally invasive technique to show nerve ischaemia in diabetic neuropathy. Diabetologia, 1999; 42: 737-742.
26. Scott LA, Ibrahim S, Radatz M, et al. Sural nerve oxygen saturation is unexpectedly increased in sub-clinical human diabetic neuropathy. Diabetologia 2002; 45: A29.
27. Pitei DL, Watkins PJ, Edmonds ME. NO dependent smooth muscle vasodilatation is reduced in NIDDM patients with peripheral sensory neuropathy. Diabetic Med 1997; 14: 284-290.
28. Stevens MJ, Feldman EL, Thomas T, Green D. Pathogenesis of diabetic neuropathy. In: Veves A (ed.), Clinical Management of Diabetic Neuropathy, Totowa, New Jersey: Human Press pp. 1998; 13-48.
29. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19: 257-267.
30. Yuen KC, Baker NR, Rayman G. Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: a double-blind placebo-controlled cross-over study. Diabetes Care 2002; 10: 1699-1703.
31. Boneu B, Abbal M, Plante J, Bierme R. Factor VIII complex and endothelial damage. Lancet 1975; 1: 1430.
32. Plater ME, Ford I, Dent MT, Preston F, Ward JD. Elevated von Willebrand factor antigen predicts deterioration in diabetic peripheral nerve function. Diabetologia 1996; 39: 336-343.
33. Solerte SB, Fioravanti M, Schifino N, et al. Hemorheologic and hemostatic changes in long-standing insulin-dependent (type I) diabetic patients with peripheral and autonomic cardiovascular neuropathy. Acta Diabetol Lat 1988; 25: 235-242.
34. Veves A, Akbari CM, Primavera J, et al. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 1998; 47: 457-463.
35. Carter AM, Grant PJ. Vascular Homeostasis, adhesion molecules, and Macrovascular disease in non-insulin-dependent Diabetes Mellitus. Diabetic Med 1997; 14: 423-432.
36. Borsey DQ, Prowse CV, Gray RS, et al. Platelet and coagulation factors in proliferative diabetic retinopathy. J Clin Pathol, 1984; 37: 659-664.
37. Rajbhandari SM, Scott LA, Dent MT, et al. Increased platelet activation predicts the development of diabetic neuropathy. Diabetologia 2002; 45: Suppl 2: 1212.
38. Koya D, King GL. Protein Kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859-866.
39. Wheeler GD. Ruboxistaurin (Eli Lilly). IDrugs. 2003; 6:159-163.
40. Standl E, Meier M. Pathophysiology of vascular disease in diabetes. In: McNally PG (ed.), Diabetes and cardiovascular complications, London: Science Press. 1999; pp. 7-12.
41. Baynes JW. Role of oxidative stress in development of complication in diabetes. Diabetes 1991; 40: 405-412.
42. Ametov AS, Barinov A, Dyck PJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care 2003; 26: 770-776.
43. Brownlee M, Cerami A, Vlassara H. Advanced glycsylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-1321.
44. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biological, and clinical implications for diabetes and ageing. Laboratory Investigation 1994; 70: 138-151.
45. Wada R, Nishizawa Y, Yagihashi N, et al. Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy. Eur J Clin Invest 2001; 31: 513-520.
46. Gabbay KH. The sorbitol pathway and the complications of diabetes. New Engl J Med 1973; 288: 831-836.
47. Kato N, Mizuno K, Makino M, Suzuki T, Yagihashi S. Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats. Diabetes Res Clin Pract 2000; 50: 77-85.
48. Obrosova IG, Van Huysen C, Fathallah L, et al. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J 2002; 16: 123-125.
49. Jamal GA, Carmichael H. The effect of Y - Linolenic Acid on human diabetic peripheral neuropathy: A double-blind placebo-controlled trial. Diabetic Medicine 1990; 7: 319-323.
50. Sima AAF, Sugimoto K. Experimental diabetic neuropathy: an update". Diabetologia 1999; 42: 773-788.
51. Coste T, Pierlovisi M, Leonardi J, et al. Beneficial effects of gamma linolenic acid supplementation on nerve conduction velocity, Na+, K+ ATPase activity, and membrane fatty acid composition in sciatic nerve of diabetic rats. J Nutr Biochem. 1999; 10: 411-420.
52. Ejskjaer NT, Zanone MM, Peakman M. Autoimmunity in diabetic autonomic neuropathy: does the immune system get on your nerves? Diabetic Med 1998; 15: 723-729.
53. Dejgaard A. Pathophysiology and treatment of diabetic neuropathy". Diabetic Med 1998; 15: 97-112.
54. Zanone MM, Favaro E, Catalfamo E, et al. Autonomic function and autoantibodies to autonomic nervous tissues at follow-up in a cohort of young patients with type 1 diabetes. Effects of serum from diabetic patients on human adrenergic cells. J Neuroimmunol 2003; 139: 66-75.
55. Shaw JE, Abbott CA, Gokal R, Boulton AJM. Renal transplantation: a cure for diabetic gustatory sweating". Diabetic Med 1997; 14: S2.
56. Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 2001; 24: 1217-1281.
57. Anand P, Terenghi G, Warner G, et al. The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med 1996; 2: 703-707.
58. Zanone MM, Banga JP, Peakman M, et al. An investigation of antibodies to nerve growth factor in diabetic autonomic neuropathy. Diabet Med 1994; 11: 378-383.
59. Apfel SC, Schwartz S, Adornato BT, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. JAMA. 2000; 284: 2215-2221.
60. Jude EB, Abbott CA, Young MJ, et al. The potential role of cell adhesion molecules in the pathogenesis of diabetic neuropathy. Diabetologia 1998; 41: 330-336.